Skip to main content
Premium Trial:

Request an Annual Quote

GE Capital Unit and Investment Bank Will Lend Inverness $1.3B to Buy Biosite

NEW YORK (GenomeWeb News) — Biosite today said that Inverness Medical Innovations plans to buy the company with financial backing from General Electric Capital Corporation and UBS Loan Finance and Securities.
In a revised commitment letter Inverness sent to Biosite, disclosed yesterday, Biosite said that GECC and UBSS would loan Biosite $1.3 billion. GECC will provide 40 percent of the amount and UBSS will drum up the 60-percent balance. 
The commitment letters can be seen here and here.
Inverness currently owns around 5 percent Biosite, or around 799,000 shares, according to Nasdaq. Based on yesterday’s closing price of $93.67 and that the remaining 95 percent of the company that Inverness wants to buy represents around 15 million shares, Inverness will need to come up with approximately $1.42 billion.
According to the revised commitment letter, the financing would include a $1.15-billion loan facility and $150-million revolving facility. These figures would depend on several conditions, including the possibility that other lenders may be brought into the deal.
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.